10x Genomics TXG
85.71
1.60
1.90%
as of 25 Sep
- Market cap
- $11.1B
- P/E
- 0.0×
Follow TXG
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (9.40%) | (2.98%) | (5.78%) | (10.12%) |
+8 more TTM periods Free account |
|
| (7.47%) | (2.36%) | (4.44%) | (7.77%) | ||
ROIC |
(20.20%) | (8.81%) | (13.97%) | (18.83%) | |
Return on Tangible Assets |
(9.74%) | (2.92%) | (5.75%) | (10.24%) | |
Average Days of Receivables |
29.96 | 32.08 | 46.84 | 54.93 | |
Free Cash Flow per Share |
0.93 | 0.95 | 1.04 | 0.65 | |
Free Cash Flow |
121.44 | 122.18 | 130.12 | 81.65 | |
Capital Expenditures |
(5.65) | (5.64) | (5.93) | (6.87) | |
Piotroski F-Score |
4.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
9.23% | 9.44% | 10.31% | 6.99% | |
Accounts Receivable Turnover |
7.27 | 11.75 | 7.52 | 7.13 | |
Accounts Payable Turnover |
10.09 | 14.13 | 15.52 | 9.03 | |
Inventory Turnover |
3.04 | 3.03 | 2.85 | 2.56 | |
Average Days of Payables |
40.85 | 32.76 | 23.36 | 32.97 | |
Days of Inventory on Hand |
103.88 | 100.55 | 103.37 | 113.06 | |
Tax Rate |
0.00 | 0.18 | 0.09 | 0.04 | |
Research and Development Expense of Revenue |
36.76% | 36.20% | 37.12% | 38.89% | |
Selling, General and Administrative Expense of Revenue |
48.14% | 45.83% | 49.18% | 51.94% | |
Share Based Compensation of Revenue |
16.01% | 15.76% | 16.97% | 18.14% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.69) | (5.64) | (3.12) | (1.16) | |
Depreciation/Fixed assets |
0.22 | 0.21 | 0.19 | 0.17 | |
Capex/Depreciation |
(0.12) | (0.12) | (0.14) | (0.17) | |
Revenue per Share |
4.75 | 4.98 | 5.15 | 5.11 | |
Operating CF per Share |
0.98 | 1.00 | 1.09 | 0.71 | |
Capex per Share |
(0.04) | (0.04) | (0.05) | (0.05) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(12.18%) | (3.55%) | (6.77%) | (11.89%) |
Columns are period end dates